Bristol-Myers Squibb Co.
BMY
Market Cap$103.21B
Close$
Earnings Call Q2 2024
July 26, 2024 - AI Summary
Bristol Myers Squibb (BMS) reported strong second-quarter results, with growth portfolio revenues increasing 18% YoY or 21% excluding the impact of foreign exchange.
The company is focused on reshaping its portfolio to prioritize transformational medicines where it has a competitive advantage. It is accelerating first or best-in-class treatments and discontinuing programs that do not meet ROI thresholds.
BMS is driving operational excellence by streamlining operations, improving R&D productivity, and emphasizing speed and accountability.
Exclusive for Stockcircle Pro members
Sign up
$57.51
7% upside
Current Fair Value
7% upsideUndervalued by 7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $103.21 Billion |
|---|---|
| Enterprise Value | $152.18 Billion |
| Dividend Yield | $2.4 (4.65527401296406%) |
| Earnings per Share | $3.88 |
| Beta | 0.46 |
| Outstanding Shares | 2,027,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -15.78 |
|---|---|
| PEG | 83.22 |
| Price to Sales | 2.44 |
| Price to Book Ratio | 6.72 |
| Enterprise Value to Revenue | 3.27 |
| Enterprise Value to EBIT | 16.04 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | 3.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Bristol-Myers Squibb Co.
30,250 employees
CEO: Giovanni Caforio Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.